l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial.

Houjeghani S, Kheirouri S, Faraji E, Jafarabadi MA

Nutrition research (New York, N.Y.)17 Nov 2017Cited by 74 (Europe PMC)

PMID29420997DOI10.1016/j.nutres.2017.11.003PepBankPUB-29420997

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study21

21 results from studies that gave the peptide. 21 results from people.

01HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, carnosine significantly decreased fat mass by 1.5% compared with placebo.
In plain wordsIn people with type 2 diabetes, carnosine reduced fat mass by 1.5% compared with placebo.
Peptide
L-carnosine
Outcome
DecreaseFat mass
Study
n = 54
Comparator
placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Measurements
Fat mass decrease
1.5%
versus placebo
Source sentences
Summary
l-Carnosine supplementation resulted in significant decrease in fat mass and an increase in fat-free mass in the intervention group compared with the placebo group (1.5% and 1.7%, respectively) (P<.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Summary · context
Blood samples and dietary intakes information were collected at baseline and after 12 weeks of intervention.
Report a problemFND-2942099701
02HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, carnosine significantly increased fat-free mass by 1.7% compared with placebo.
In plain wordsIn people with type 2 diabetes, carnosine increased fat-free mass by 1.7% compared with placebo.
Peptide
L-carnosine
Outcome
IncreaseFat-free mass
Study
n = 54
Comparator
placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Measurements
Fat-free mass increase
1.7%
versus placebo
Source sentences
Summary
l-Carnosine supplementation resulted in significant decrease in fat mass and an increase in fat-free mass in the intervention group compared with the placebo group (1.5% and 1.7%, respectively) (P<.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Summary · context
Blood samples and dietary intakes information were collected at baseline and after 12 weeks of intervention.
Report a problemFND-2942099702
03HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, carnosine significantly reduced fasting blood glucose by 13.1 mg/dL compared with placebo.
In plain wordsIn people with type 2 diabetes, carnosine reduced fasting glucose by 13.1 mg/dL compared with placebo.
Peptide
L-carnosine
Outcome
DecreaseFasting blood glucose
Study
n = 54
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Measurements
Fasting glucose reduction
13.1 mg/dL
versus placebo
Source sentences
Summary
A significant reduction in fasting blood glucose (13.1 mg/dL); glycated hemoglobin (.6%); and serum levels of triglycerides (29.8 mg/dL), carboxymethyl lysine (91.8 ng/mL), and tumor necrosis factor-α was detected in the l-carnosine group compared with the placebo group (P<.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Summary · context
Blood samples and dietary intakes information were collected at baseline and after 12 weeks of intervention.
Report a problemFND-2942099703
04HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, carnosine significantly reduced glycated hemoglobin by .6% compared with placebo.
In plain wordsIn people with type 2 diabetes, carnosine reduced glycated hemoglobin by .6% compared with placebo.
Peptide
L-carnosine
Outcome
DecreaseGlycated hemoglobin
Study
n = 54
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Measurements
Glycated hemoglobin reduction
0.6%
versus placebo
Source sentences
Summary
A significant reduction in fasting blood glucose (13.1 mg/dL); glycated hemoglobin (.6%); and serum levels of triglycerides (29.8 mg/dL), carboxymethyl lysine (91.8 ng/mL), and tumor necrosis factor-α was detected in the l-carnosine group compared with the placebo group (P<.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Summary · context
Blood samples and dietary intakes information were collected at baseline and after 12 weeks of intervention.
Report a problemFND-2942099704
05HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, carnosine significantly reduced triglycerides by 29.8 mg/dL compared with placebo.
In plain wordsIn people with type 2 diabetes, carnosine reduced triglycerides by 29.8 mg/dL compared with placebo.
Peptide
L-carnosine
Outcome
DecreaseTriglycerides
Study
n = 54
Comparator
placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Measurements
Triglyceride reduction
29.8 mg/dL
versus placebo
Source sentences
Summary
A significant reduction in fasting blood glucose (13.1 mg/dL); glycated hemoglobin (.6%); and serum levels of triglycerides (29.8 mg/dL), carboxymethyl lysine (91.8 ng/mL), and tumor necrosis factor-α was detected in the l-carnosine group compared with the placebo group (P<.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Summary · context
Blood samples and dietary intakes information were collected at baseline and after 12 weeks of intervention.
Report a problemFND-2942099705
06HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, carnosine significantly reduced carboxymethyl lysine by 91.8 ng/mL compared with placebo.
In plain wordsIn people with type 2 diabetes, carnosine reduced carboxymethyl lysine by 91.8 ng/mL compared with placebo.
Peptide
L-carnosine
Outcome
DecreaseCarboxymethyl lysine
Study
n = 54
Comparator
placebo
Outcome group
Aging markers · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Measurements
Carboxymethyl lysine reduction
91.8 ng/mL
versus placebo
Source sentences
Summary
A significant reduction in fasting blood glucose (13.1 mg/dL); glycated hemoglobin (.6%); and serum levels of triglycerides (29.8 mg/dL), carboxymethyl lysine (91.8 ng/mL), and tumor necrosis factor-α was detected in the l-carnosine group compared with the placebo group (P<.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Summary · context
Blood samples and dietary intakes information were collected at baseline and after 12 weeks of intervention.
Report a problemFND-2942099706
07HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, carnosine significantly reduced TNF-α compared with placebo.
In plain wordsIn people with type 2 diabetes, carnosine reduced TNF-α compared with placebo.
Peptide
L-carnosine
Outcome
DecreaseTNF-α
Study
n = 54
Comparator
placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
A significant reduction in fasting blood glucose (13.1 mg/dL); glycated hemoglobin (.6%); and serum levels of triglycerides (29.8 mg/dL), carboxymethyl lysine (91.8 ng/mL), and tumor necrosis factor-α was detected in the l-carnosine group compared with the placebo group (P<.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Summary · context
Blood samples and dietary intakes information were collected at baseline and after 12 weeks of intervention.
Report a problemFND-2942099707
08HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, adjusted dietary intake did not differ significantly between carnosine and placebo.
In plain wordsIn people with type 2 diabetes, dietary intake did not differ significantly between carnosine and placebo after adjustment.
Peptide
L-carnosine
Outcome
No significant changeDietary intake
Study
n = 54
Comparator
placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were observed in dietary intake, body mass index,
2 context sentences(design, population, supporting numbers)
Summary · context
between the groups after adjusting for baseline values and covariates (P>.05).
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Report a problemFND-2942099709
09HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, adjusted body mass index did not differ significantly between carnosine and placebo.
In plain wordsIn people with type 2 diabetes, body mass index did not differ significantly between carnosine and placebo after adjustment.
Peptide
L-carnosine
Outcome
No significant changeBody mass index
Study
n = 54
Comparator
placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were observed in dietary intake, body mass index,
2 context sentences(design, population, supporting numbers)
Summary · context
between the groups after adjusting for baseline values and covariates (P>.05).
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Report a problemFND-2942099710
10HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, adjusted systolic blood pressure did not differ significantly between carnosine and placebo.
In plain wordsIn people with type 2 diabetes, systolic blood pressure did not differ significantly between carnosine and placebo after adjustment.
Peptide
L-carnosine
Outcome
No significant changeSystolic blood pressure
Study
n = 54
Comparator
placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were observed in dietary intake, body mass index, systolic and diastolic blood pressure,
2 context sentences(design, population, supporting numbers)
Summary · context
between the groups after adjusting for baseline values and covariates (P>.05).
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Report a problemFND-2942099711
11HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, adjusted diastolic blood pressure did not differ significantly between carnosine and placebo.
In plain wordsIn people with type 2 diabetes, diastolic blood pressure did not differ significantly between carnosine and placebo after adjustment.
Peptide
L-carnosine
Outcome
No significant changeDiastolic blood pressure
Study
n = 54
Comparator
placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were observed in dietary intake, body mass index, systolic and diastolic blood pressure,
2 context sentences(design, population, supporting numbers)
Summary · context
between the groups after adjusting for baseline values and covariates (P>.05).
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Report a problemFND-2942099712
12HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, adjusted fasting insulin did not differ significantly between carnosine and placebo.
In plain wordsIn people with type 2 diabetes, fasting insulin did not differ significantly between carnosine and placebo after adjustment.
Peptide
L-carnosine
Outcome
No significant changeFasting insulin
Study
n = 54
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were observed in dietary intake, body mass index, systolic and diastolic blood pressure, fasting insulin levels,
2 context sentences(design, population, supporting numbers)
Summary · context
between the groups after adjusting for baseline values and covariates (P>.05).
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Report a problemFND-2942099713
13HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, adjusted HOMA insulin resistance did not differ significantly between carnosine and placebo.
In plain wordsIn people with type 2 diabetes, insulin resistance did not differ significantly between carnosine and placebo after adjustment.
Peptide
L-carnosine
Outcome
No significant changeHOMA insulin resistance
Study
n = 54
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were observed in dietary intake, body mass index, systolic and diastolic blood pressure, fasting insulin levels, homeostasis model assessment of insulin resistance and secretion,
2 context sentences(design, population, supporting numbers)
Summary · context
between the groups after adjusting for baseline values and covariates (P>.05).
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Report a problemFND-2942099714
14HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, adjusted HOMA insulin secretion did not differ significantly between carnosine and placebo.
In plain wordsIn people with type 2 diabetes, insulin secretion did not differ significantly between carnosine and placebo after adjustment.
Peptide
L-carnosine
Outcome
No significant changeHOMA insulin secretion
Study
n = 54
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were observed in dietary intake, body mass index, systolic and diastolic blood pressure, fasting insulin levels, homeostasis model assessment of insulin resistance and secretion,
2 context sentences(design, population, supporting numbers)
Summary · context
between the groups after adjusting for baseline values and covariates (P>.05).
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Report a problemFND-2942099715
15HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, adjusted total cholesterol did not differ significantly between carnosine and placebo.
In plain wordsIn people with type 2 diabetes, total cholesterol did not differ significantly between carnosine and placebo after adjustment.
Peptide
L-carnosine
Outcome
No significant changeTotal cholesterol
Study
n = 54
Comparator
placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were observed in dietary intake, body mass index, systolic and diastolic blood pressure, fasting insulin levels, homeostasis model assessment of insulin resistance and secretion, total cholesterol,
2 context sentences(design, population, supporting numbers)
Summary · context
between the groups after adjusting for baseline values and covariates (P>.05).
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Report a problemFND-2942099716
16HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, adjusted LDL cholesterol did not differ significantly between carnosine and placebo.
In plain wordsIn people with type 2 diabetes, LDL cholesterol did not differ significantly between carnosine and placebo after adjustment.
Peptide
L-carnosine
Outcome
No significant changeLDL cholesterol
Study
n = 54
Comparator
placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were observed in dietary intake, body mass index, systolic and diastolic blood pressure, fasting insulin levels, homeostasis model assessment of insulin resistance and secretion, total cholesterol, low-density lipoprotein cholesterol,
2 context sentences(design, population, supporting numbers)
Summary · context
between the groups after adjusting for baseline values and covariates (P>.05).
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Report a problemFND-2942099717
17HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, adjusted HDL cholesterol did not differ significantly between carnosine and placebo.
In plain wordsIn people with type 2 diabetes, HDL cholesterol did not differ significantly between carnosine and placebo after adjustment.
Peptide
L-carnosine
Outcome
No significant changeHDL cholesterol
Study
n = 54
Comparator
placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
high-density lipoprotein cholesterol, sRAGE, interleukin (IL)-6, and IL-1β levels between the groups after adjusting for baseline values and covariates (P>.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Report a problemFND-2942099718
18HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, adjusted sRAGE did not differ significantly between carnosine and placebo.
In plain wordsIn people with type 2 diabetes, sRAGE did not differ significantly between carnosine and placebo after adjustment.
Peptide
L-carnosine
Outcome
No significant changesRAGE
Study
n = 54
Comparator
placebo
Outcome group
Aging markers · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
high-density lipoprotein cholesterol, sRAGE, interleukin (IL)-6, and IL-1β levels between the groups after adjusting for baseline values and covariates (P>.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Report a problemFND-2942099719
19HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, adjusted IL-6 did not differ significantly between carnosine and placebo.
In plain wordsIn people with type 2 diabetes, IL-6 did not differ significantly between carnosine and placebo after adjustment.
Peptide
L-carnosine
Outcome
No significant changeIL-6
Study
n = 54
Comparator
placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
high-density lipoprotein cholesterol, sRAGE, interleukin (IL)-6, and IL-1β levels between the groups after adjusting for baseline values and covariates (P>.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Report a problemFND-2942099720
20HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, adjusted IL-1β did not differ significantly between carnosine and placebo.
In plain wordsIn people with type 2 diabetes, IL-1β did not differ significantly between carnosine and placebo after adjustment.
Peptide
L-carnosine
Outcome
No significant changeIL-1β
Study
n = 54
Comparator
placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Source sentences
Summary
high-density lipoprotein cholesterol, sRAGE, interleukin (IL)-6, and IL-1β levels between the groups after adjusting for baseline values and covariates (P>.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Report a problemFND-2942099721
21HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, serum pentosidine fell by 2.8 ng/mL from baseline in the carnosine group, and no placebo comparison is reported for this result.
In plain wordsIn people with type 2 diabetes, serum pentosidine fell from baseline in the carnosine group, and no placebo comparison was reported.
Peptide
L-carnosine
Outcome
DecreasePentosidine
Study
n = 27
Comparator
baseline
Outcome group
Aging markers · Metabolic and weight
Studied dose
2 capsules, 500 mg each · 12 weeksAs given in this study (human).
Measurements
Pentosidine reduction
2.8 ng/mL
versus baseline
Source sentences
Summary
In the l-carnosine group, a significant reduction in serum pentosidine levels (2.8 ng/mL) was observed compared with those at baseline (P<.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27).
Summary · context
Blood samples and dietary intakes information were collected at baseline and after 12 weeks of intervention.
Report a problemFND-2942099708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial.

Summary

Results from this study21

Version history

Subjects

Publication types

MeSH terms

Keywords